Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Rhea-AI Summary
Phio Pharmaceuticals (NASDAQ: PHIO) will participate in Renmark Financial Communications’ Live Virtual Non-Deal Roadshow Series on Thursday, May 28, 2026 at 12 PM EDT. CEO and Chairman Robert Bitterman will present the company’s INTASYL siRNA gene silencing platform and lead candidate PH-762 for cutaneous carcinomas, followed by a live Q&A.
PH-762, which silences the PD-1 gene, is in a Phase 1b trial (NCT# 06014086) for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma as a potential non-surgical skin cancer treatment.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – PHIO
On the day this news was published, PHIO declined 0.92%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PHIO was flat on the day while momentum names like PHGE showed strong upside moves, indicating this investor-relations event was stock-specific rather than part of a broad biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 12 | Fireside chat announced | Positive | +1.9% | Virtual Force Family Office chat on PH-762 data and skin cancer innovations. |
| May 07 | Q1 2026 earnings | Neutral | -6.1% | Q1 results with higher R&D, wider net loss, and PH-762 progress update. |
| Apr 23 | Renmark roadshow | Positive | -1.6% | April Renmark virtual roadshow on INTASYL platform and PH-762 progress. |
| Apr 13 | Fireside chat | Positive | +2.5% | ‘Nobel Prize Winning Science’ virtual chat highlighting Phase 1b PH-762 data. |
| Apr 09 | Conference presentation | Neutral | -3.9% | Centri Capital Conference talk on INTASYL and PH-762 immuno-oncology program. |
Recent IR- and event-focused news often had mixed or negative price reactions despite generally positive clinical messaging on PH-762.
Over the past few months, PHIO has repeatedly highlighted its INTASYL siRNA platform and lead candidate PH-762, including fireside chats on April 15 and May 19, 2026, multiple conference and roadshow appearances, and completion of a Phase 1b trial with favorable safety and pathology signals. Q1 2026 results on May 7, 2026 showed higher R&D spend and a wider net loss. Today’s non-deal roadshow notice continues this pattern of outreach centered on PH-762 and its Phase 1b program in skin cancers.
Regulatory & Risk Context
An effective S-3 shelf filed on 2025-11-20 registers up to 11,763,800 warrant shares for resale by existing holders. Phio would only receive cash upon warrant exercise, with potential proceeds of about $24.5 million earmarked for working capital and PH-762 development. The company is not selling primary shares under this resale prospectus.
Market Pulse Summary
This announcement highlights another investor-relations touchpoint focused on Phio’s INTASYL siRNA platform and lead candidate PH-762, now in a Phase 1b trial (NCT# 06014086) across several skin cancers. It follows a series of fireside chats, conference talks, and financial updates in 2026 centered on the same program. Investors may watch for forthcoming FDA interactions, later-stage trial design decisions, and any balance sheet or capital-raising moves disclosed in future filings.
Key Terms
sirna medical
gene silencing medical
immuno-oncology medical
phase 1b medical
cutaneous squamous cell carcinoma medical
merkel cell carcinoma medical
pd-1 medical
nct# 06014086 medical
AI-generated analysis. Not financial advice.
Live Presentation and Q&A: Thursday, May 28, 2026 12 PM EDT
King of Prussia, Pennsylvania--(Newsfile Corp. - May 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas. The presentation will be followed by a live Q&A session.
"We look forward to participating in the Renmark Virtual Non-Deal Roadshow, where we will discuss why we believe INTASYL represents a differentiated and promising approach in immuno-oncology," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.
Phio's presentation and live Q&A will take place on Thursday May 28, 2026, at 12 PM EDT in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc.
REGISTER HERE: Renmark Virtual Non-Deal Roadshow NASDAQ - PHIO | Event Registration | Renmark Financial Communications
Please Note: If the link does not work, please copy and paste into your browser. To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.
A replay of the event may be accessed on the Renmark Financial Communications Inc. website at https://www.renmarkfinancial.com/vndrs.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements, among other things, regarding the anticipated benefits of our INTASYL™ RNAi platform, the results from our ongoing clinical trials, our expectations that our cash runway will extend into the first half of 2027, our expectations regarding timing of FDA submissions intended to propose and seek guidance for next steps in clinical study design for PH-762, our expectations that such FDA submissions and any related FDA meetings will clarify next steps in advancing the PH-762 development program, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact of future FDA interactions on the development of our product candidates; the impact to our business and operations by inflationary pressures; recession fears; the development of our product candidates, results from our nonclinical, preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the U.S. Securities and Exchange Commission. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
Renmark Financial Communications Inc.
James R. Kautz: jkautz@renmarkfinancial.com
Tel: (416)-644-2020 or (212)-812-7680
www.renmarkfinancial.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298745